Skye Bioscience (SKYE) announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its common stock to one new non-executive employee under the Company’s Amended and Restated 2024 Inducement Equity Incentive Plan. The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience announces new preclinical data for nimacimab
- Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress
- Skye Bioscience: Strategic Advancements and Robust Financial Health Support Buy Rating
- Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum
- Skye Bioscience Reports 2024 Financial Results and Trial Progress